Rosen Law Firm Files Class Action Against Atara Biotherapeutics
Analysis based on 86 articles · First reported Mar 23, 2026 · Last updated Apr 16, 2026
The market is negatively impacted by the news of a class action lawsuit against Atara Biotherapeutics, as it highlights potential misrepresentation and regulatory hurdles for its key drug. This could lead to a decrease in investor confidence and a decline in Atara Biotherapeutics' stock price.
Rosen Law Firm has announced a class action lawsuit against Atara Biotherapeutics, reminding investors of the May 22, 2026 lead plaintiff deadline. The lawsuit alleges that Atara Biotherapeutics made false and misleading statements between May 20, 2024, and January 9, 2026, regarding the regulatory approval prospects of its drug, tabelecleucel. Specifically, the suit claims that manufacturing issues and deficiencies in the ALLELE study made it unlikely for the United States===Food and Drug Administration to approve the Biologics License Application. These undisclosed issues allegedly overstated tabelecleucel's regulatory prospects, subjected Atara Biotherapeutics to heightened regulatory scrutiny, and jeopardized ongoing clinical trials, ultimately having a significant negative impact on the company's business and financial condition. Investors who purchased Atara Biotherapeutics securities during the specified period may be entitled to compensation.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard